特力利汀

化合物

特力利汀(國際非專利藥品名稱:Teneligliptin,商品名爲「Tenelia」),係治療2型糖尿病的藥物。目前,該藥已在日本通過相關審批 [1] It belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins".[2]

特力利汀
Teneligliptin
臨床資料
商品名英语Drug nomenclature「Tenelia」
法律規範狀態
法律規範
  • 在日本通過審批
识别信息
  • {(2S,4S)-4-[4-(3-Methyl-1-phenyl-1H-pyrazol-5-yl)-1-piperazinyl]-2-pyrrolidinyl}(1,3-thiazolidin-3-yl)methanone
CAS号760937-92-6  ☒N
PubChem CID
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
化学信息
化学式C22H30N6OS
摩尔质量426.58 g/mol
3D模型(JSmol英语JSmol
  • CC1=NN(C(=C1)N2CCN(CC2)[C@H]3C[C@H](NC3)C(=O)N4CCSC4)C5=CC=CC=C5
  • InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
  • Key:WGRQANOPCQRCME-PMACEKPBSA-N

參考

  1. ^ Joanne Bronson, Amelia Black, T. G. Murali Dhar, Bruce A. Ellsworth, and J. Robert Merritt. Teneligliptin (Antidiabetic). Annual Reports in Medicinal Chemistry: 523–524. doi:10.1016/b978-0-12-417150-3.00028-4.  |chapter=被忽略 (帮助)
  2. ^ Kishimoto, M. Teneligliptin: A DPP-4 inhibitor for the treatment of type 2 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy. 2013, 6: 187–95. PMC 3650886 . PMID 23671395. doi:10.2147/DMSO.S35682.